{"title":"The First Molecular Profiling of JAK2 Exon 12 and Flanking Intronic Sequences in Indonesia.","authors":"Farmaditya Eka Putra Mundhofir, Nani Maharani, Raisa Tahira, Amelia Syabani, Nydia Rena Benita Sihombing, Ferdy Kurniawan Cayami, Endang Mahati, Tri Indah Winarni","doi":"10.31557/APJCP.2026.27.9.3237","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Data on JAK2 Exon 12 mutations in Indonesia are not available. This study aimed to explore the presence of known JAK2 exon 12 coding mutations in V617F-negative myeloproliferative neoplasm (MPN) patients in Indonesia and to describe any novel intronic changes downstream of exon 12.</p><p><strong>Methods: </strong>A total of 198 V617F-negative MPN samples were screened using allele-specific polymerase chain reaction (AS-PCR) for four commonly reported canonical exon 12 mutations. Of these, 57 cases were selected at random or for atypical PCR band patterns and underwent bidirectional Sanger sequencing of a 496-bp fragment covering exon 12 plus ~250 bp of the adjacent region. Variants were cross-referenced with gnomAD v4.1.0. Furthermore, SpliceAI was used to predict splice site gain or loss.</p><p><strong>Results: </strong>No coding mutations were identified in exon 12. However, two intronic variants were detected adjacently downstream: NC_000009.12:g.5070231_5070235delTCTTA in 29 of 57 cases (50.9%), which was not present in the gnomAD database, and NC_000009.12:g.5070319C>T in 1 of 57 cases (1.8%), corresponding to a rare gnomAD entry. The SpliceAI Δ scores remained below 0.2, a high-sensitivity threshold, indicating no predicted impact on canonical splicing.</p><p><strong>Conclusion: </strong>Classic exon 12 coding mutations are apparently absent in Indonesian V617F-negative MPNs. We report a highly frequent downstream intronic deletion not recorded in global databases, as well as a rare single nucleotide variant (SNV) that aligns with gnomAD data. Although in silico tools suggest minimal splice disruption, RNA-level assays are needed to rule out the subtle effects of the variant. Our workflow, which combines allele-specific PCR and targeted sequencing, may be suitable for laboratories facing resource constraints.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"27 9","pages":"3237-3243"},"PeriodicalIF":0.0000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2026.27.9.3237","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Data on JAK2 Exon 12 mutations in Indonesia are not available. This study aimed to explore the presence of known JAK2 exon 12 coding mutations in V617F-negative myeloproliferative neoplasm (MPN) patients in Indonesia and to describe any novel intronic changes downstream of exon 12.
Methods: A total of 198 V617F-negative MPN samples were screened using allele-specific polymerase chain reaction (AS-PCR) for four commonly reported canonical exon 12 mutations. Of these, 57 cases were selected at random or for atypical PCR band patterns and underwent bidirectional Sanger sequencing of a 496-bp fragment covering exon 12 plus ~250 bp of the adjacent region. Variants were cross-referenced with gnomAD v4.1.0. Furthermore, SpliceAI was used to predict splice site gain or loss.
Results: No coding mutations were identified in exon 12. However, two intronic variants were detected adjacently downstream: NC_000009.12:g.5070231_5070235delTCTTA in 29 of 57 cases (50.9%), which was not present in the gnomAD database, and NC_000009.12:g.5070319C>T in 1 of 57 cases (1.8%), corresponding to a rare gnomAD entry. The SpliceAI Δ scores remained below 0.2, a high-sensitivity threshold, indicating no predicted impact on canonical splicing.
Conclusion: Classic exon 12 coding mutations are apparently absent in Indonesian V617F-negative MPNs. We report a highly frequent downstream intronic deletion not recorded in global databases, as well as a rare single nucleotide variant (SNV) that aligns with gnomAD data. Although in silico tools suggest minimal splice disruption, RNA-level assays are needed to rule out the subtle effects of the variant. Our workflow, which combines allele-specific PCR and targeted sequencing, may be suitable for laboratories facing resource constraints.
期刊介绍:
Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation.
The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally.
The APJCP publishes original research results under the following categories:
-Epidemiology, detection and screening.
-Cellular research and bio-markers.
-Identification of bio-targets and agents with novel mechanisms of action.
-Optimal clinical use of existing anti-cancer agents, including combination therapies.
-Radiation and surgery.
-Palliative care.
-Patient adherence, quality of life, satisfaction.
-Health economic evaluations.